Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function

The Lancet

Volumn 383, Issue 9920, 2014, Pages 923-925

  Massie, John ^a,b,c   Castellani, Carlo ^d   Grody, Wayne W ^e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR;

CYSTIC FIBROSIS; DISEASE CARRIER; GENE; GENE MUTATION; GENETIC COUNSELING; GENOTYPE; HUMAN; NEWBORN SCREENING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; DRUG EFFECT; DRUG TARGETING; GENETIC SCREENING; HETEROZYGOTE; NOTE;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HETEROZYGOTE DETECTION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; QUINOLONES;

EID: 84895741970     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61092-2     Document Type: Note

References (25)

1. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001; 3: 149-54.
2. Cystic Fibrosis Population Screening Position Paper. Ed: Human Genetics Society of Australasia, 2010. http://www.hgsa.org.au/documents/item/27 (accessed June 20, 2013).
3. Castellani C, Macek M Jr, Cassiman JJ, et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 2010; 9: 165-78.
4. Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. JAMA 2009; 302: 2573-79.
5. Cunningham S, Marshall T. Influence of five years of antenatal screening on the paediatric cystic fibrosis population in one region. Arch Dis Child 1998; 78: 345-48.
6. Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med 2008; 358: 973-74.
7. Witt D, Wold C, Goonewardena P, Louie E, Rosenfeld S. Cystic fibrosis prenatal screening of 103,600 individuals in an HMO: molecular/clinical outcomes and a dramatic reduction in CF incidence. Annual Meeting, American Society of Human Genetics; Philadelphia, PA, USA; Nov 11-15, 2008. 686 (abstr).
8. Achterbergh R, Lakeman P, Stemerding D, Moors EH, Cornel MC. Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: a sociotechnical analysis. Health Policy 2007; 83: 277-86.
9. Boyle MP, Boeck. KD. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1: 158-63.
10. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med 2012; 186: 593-97.
11. Ramsey BW, Davies J, McElvaney NG, et al., and the VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-72.
12. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
13. Davies JC, Wainwright CE, Canny GJ, et al., and the on behalf of the VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; published online April 3. DOI:10.1164/rccm.201301- 0153OC.
14. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-54.
15. Borthwick LA, Botha P, Verdon B, et al. Is CFTR-delF508 really absent from the apical membrane of the airway epithelium? PLoS One 2011; 6: e23226.
16. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843-48.
17. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
18. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12-18.
19. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6: 387-91.
20. Hoo AF, Thia LP, Nguyen TT, et al., and the London Cystic Fibrosis Collaboration. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012; 67: 874-81.
21. Pillarisetti N, Williamson E, Linnane B, et al., and the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 75-81.
22. Meyerholz DK, Stoltz DA, Namati E, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med 2010; 182: 1251-61.
23. Beutler E. Carrier screening for Gaucher disease: more harm than good? JAMA 2007; 298: 1329-31.
24. Radhakrishnan M, van Gool K, Hall J, Delatycki M, Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 2008; 85: 133-47.
25. van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013; 16: 345-55.